Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system - PubMed (original) (raw)

Affiliations

PMID: 11561058

Review

Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system

D D Schoepp. J Pharmacol Exp Ther. 2001 Oct.

Abstract

Metabotropic glutamate (mGlu) receptors, which include mGlu1-8 receptors, are a heterogeneous family of G-protein-coupled receptors which function to modulate brain excitability via presynaptic, postsynaptic and glial mechanisms. Certain members of this receptor family have been shown to function as presynaptic regulatory mechanisms to control release of neurotransmitters. In general, Gi-coupled mGlu receptor subtypes appear to negatively modulate excitatory (and possibly also inhibitory) neurotransmitter output when activated. Localization studies have shown that mGlu7 is restricted to the presynaptic grid at the site of vesicle fusion. These studies along with other evidence suggest that mGlu7 is the nerve terminal autoreceptor that regulates physiological release of glutamate. Other mGlu subtypes, in particular mGlu2, mGlu8, and possibly mGlu4, are also localized presynaptically, but at perisynaptic sites outside the active zone of neurotransmitter release. Gi-coupled mGlu receptors also may exist on presynaptic elements of neighboring gamma-aminobutyric acid (GABA) neurons where they play a role in heterosynaptic suppressions of GABA release. This suggests that these receptors may have evolved to monitor glutamate that has "spilled" out of the synapse. Thus, they may serve as the brain's evolutionary mechanism to prevent pathological changes in neuronal excitability and thus maintain homeostasis. Recent progress on the molecular and pharmacological aspects of these presynaptic mGlu receptors is unveiling their functions and the therapeutic directions of agents designed for these novel glutamate receptor targets.

PubMed Disclaimer

Cited by

Functional and pharmacological characteristics of metabotropic glutamate receptors 2/4 heterodimers.
Kammermeier PJ. Kammermeier PJ. Mol Pharmacol. 2012 Sep;82(3):438-47. doi: 10.1124/mol.112.078501. Epub 2012 May 31. Mol Pharmacol. 2012. PMID: 22653971 Free PMC article.
Multi-locus genome-wide association analysis supports the role of glutamatergic synaptic transmission in the etiology of major depressive disorder.
Lee PH, Perlis RH, Jung JY, Byrne EM, Rueckert E, Siburian R, Haddad S, Mayerfeld CE, Heath AC, Pergadia ML, Madden PA, Boomsma DI, Penninx BW, Sklar P, Martin NG, Wray NR, Purcell SM, Smoller JW. Lee PH, et al. Transl Psychiatry. 2012 Nov 13;2(11):e184. doi: 10.1038/tp.2012.95. Transl Psychiatry. 2012. PMID: 23149448 Free PMC article.
Developmental expression of mGlu2 and mGlu3 in the mouse brain.
McOmish CE, Demireva EY, Gingrich JA. McOmish CE, et al. Gene Expr Patterns. 2016 Nov;22(2):46-53. doi: 10.1016/j.gep.2016.10.001. Epub 2016 Nov 4. Gene Expr Patterns. 2016. PMID: 27818290 Free PMC article.
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A. Krystal JH, et al. Psychopharmacology (Berl). 2005 Apr;179(1):303-9. doi: 10.1007/s00213-004-1982-8. Epub 2004 Aug 10. Psychopharmacology (Berl). 2005. PMID: 15309376 Clinical Trial.
Group III metabotropic glutamate receptors maintain tonic inhibition of excitatory synaptic input to hypocretin/orexin neurons.
Acuna-Goycolea C, Li Y, Van Den Pol AN. Acuna-Goycolea C, et al. J Neurosci. 2004 Mar 24;24(12):3013-22. doi: 10.1523/JNEUROSCI.5416-03.2004. J Neurosci. 2004. PMID: 15044540 Free PMC article.

Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system - PubMed (original) (raw)